 |
|
Multiple Myeloma Trial Results
6. Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
(Posted: 04/04/2007) - Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that use of a low dose of the steroid dexamethasone (Decadron ®), in combination with lenalidomide (Revlimid ®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone.
7. Study Compares Stem Cell Transplant Treatments
(Posted: 03/21/2007) - Patients with newly diagnosed multiple myeloma who received a transplant of their own stem cells (autologous) and a second stem cell transplant from an HLA-matched sibling (allogeneic) had superior survival outcomes compared to patients who received two autologous stem cell transplants, according to the March 15, 2007, New England Journal of Medicine.
8. Lenalidomide Effective in Multiple Myeloma
(Posted: 06/28/2006, Reviewed: 09/29/2008) - Combining lenalidomide with dexamethasone delayed the progression of advanced multiple myeloma for more than twice as long as did dexamethasone alone in patients whose disease had come back or stopped responding to other treatments, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
9. Lower Dose of Thalidomide May Be Just as Effective in Multiple Myeloma
(Posted: 06/07/2006) - Cutting the daily dose of the drug thalidomide from 400 mg to 100 mg significantly reduced the drug's potentially severe side effects in patients with multiple myeloma that had come back or stopped responding to treatment, and without a significant impact on survival, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
10. Thalidomide Helps Elderly Multiple Myeloma Patients to Live Longer
(Posted: 06/05/2006, Reviewed: 10/06/2007) - Elderly patients with multiple myeloma who were treated with the drug thalidomide in addition to standard chemotherapy lived 15 to 21 months longer on average than patients who received either high doses of a standard drug followed by a stem cell transplant or standard chemotherapy alone, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
< Previous 1 2 3 4 Next >
|
|
|
